Andrej Spec, George R Thompson, Marisa H Miceli, Justin Hayes, Laurie Proia, David McKinsey, Ana Belen Arauz, Kathleen Mullane, Jo-Ann Young, Gerald McGwin, Rachel McMullen, Tyler Plumley, Mary K Moore, Lee Ann McDowell, Carolynn Jones, Peter G Pappas
BACKGROUND: Invasive fungal disease caused by dimorphic fungi is associated with significant morbidity and mortality. Super-bioavailability itraconazole (SUBA-itra) is a novel antifungal agent with pharmacokinetic advantages over currently available formulations. In this prospective comparative study, we report the outcomes of patients with endemic fungal infections (histoplasmosis, blastomycosis, coccidioidomycosis, and sporotrichosis). METHODS: This open-label randomized trial evaluated the efficacy, safety, and pharmacokinetics SUBA-itra compared with conventional itraconazole (c-itra) treatment for endemic fungal infections...
March 2024: Open Forum Infectious Diseases